Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.47 |
| ▸ | HCRTR2 | O43614 | 13/20 | 0.47 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1571805 | 0.78 | CNR1 (0.50) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL15173502 | 0.75 | CNR1 (0.53) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL20040371 | 0.75 | CNR1 (0.53) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL20040369 | 0.75 | CNR1 (0.53) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL15173872 | 0.75 | CNR1 (0.53) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL15174138 | 0.75 | CNR1 (0.53) | CNR1CNR2HCRTR1HCRTR2PREP | |
| SCHEMBL982517 | 0.74 | HTR4 (0.51) | CNR1CNR2 | |
| SCHEMBL984621 | 0.74 | HCRTR1 (0.42) | HCRTR1HCRTR2NPC1RAB9A | |
| SCHEMBL2127093 | 0.74 | HTR4 (0.51) | CNR1CNR2 | |
| SCHEMBL7382937 | 0.69 | EGLN1 (0.74) | CNR1CNR2PREPMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | CNR1 16/4885CNR2 18/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.